急性严重出血止血治疗临床试验的结局指标选择
本文利用CRASH-2、WOMAN和HALT-IT三项大型随机对照试验的数据,探讨急性严重出血止血治疗试验中常用结局指标(全因死亡、死因别死亡、输血和手术干预)的优缺点。结论认为全因死亡率统计效能低、缺乏外推性且可能掩盖有害效应,而死因别死亡率可避免这些缺陷,输血和手术作为结局指标效用有限。
要点
- 全因死亡率统计效能低,且因非出血死亡稀释而可能掩盖治疗有害效应。
- 死因别死亡率(如出血或血栓死亡)可避免全因死亡率的缺陷,更具外推性。
- 在无法评估死因或存在偏倚担忧时,时间别死亡率可作为死因别死亡率的替代指标。
核心结论
- 全因死亡率统计效能低、缺乏外推性且可能掩盖有害效应。
- 死因别死亡率(如出血或血栓死亡)可避免上述缺陷。
- 在某些情况下,时间别死亡率可作为死因别死亡率的替代指标。
- 输血和手术操作作为止血治疗试验的结局指标效用有限。
研究设计与样本
- 利用CRASH-2、WOMAN和HALT-IT三项大型随机对照试验的数据进行方法学探讨。
主要发现
- 急性严重出血后的许多死亡由患者合并症或并发症导致而非出血。
- 若非出血死亡不受止血干预影响,即使大型试验对全因死亡率的检验效能也很低。
- 全因死亡率可因治疗无关或治疗减少的死亡稀释而掩盖重要有害效应。
- 不同死因在不同时间间隔发生,出血死亡通常发生较早。
临床怎么用
- 在止血治疗临床试验中优先考虑死因别死亡率作为主要结局。
- 在无法评估死因或存在偏倚担忧时,可考虑使用时间别死亡率作为替代。
- 输血和手术操作不宜作为止血治疗试验的主要结局指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute severe haemorrhage is a common complication of injury, childbirth, surgery, gastrointestinal pathologies and other medical conditions. Bleeding is a major cause of death, but patients also die from non-bleeding causes, the frequency of which varies by the site of haemorrhage and between populations. Because patients can bleed to death within hours, established interventions inevitably take priority over randomisation into a trial. These circumstances raise challenges in selecting appropriate outcome measures for clinical trials of haemostatic interventions. MAIN BODY: We use data from three large randomised controlled trials in acute severe haemorrhage (CRASH-2, WOMAN and HALT-IT) to explore the strengths and limitations of outcome measures commonly used in trials of haemostatic treatments, including all-cause and cause-specific mortality, blood transfusion and surgical interventions. Many deaths following acute severe haemorrhage are due to patient comorbidities or complications rather than bleeding. If non-bleeding deaths are unaffected by a haemostatic intervention, even large trials will have low power to detect an effect on all-cause mortality. Due to the dilution from deaths unaffected or reduced by the trial treatment, all-cause mortality can also obscure important harmful effects. Additionally, because the relative contributions of different causes of death vary within and between patient populations, all-cause mortality is not generalisable. Different causes of death occur at different time intervals from bleeding onset, with bleeding deaths generally occurring early. Time-specific mortality can therefore be used as a proxy for cause in un-blinded trials where bias is a concern or in situations where cause of death cannot be assessed. Urgent treatment is critical, and so post-randomisation blood transfusion and surgery are often planned before or at the time of randomisation and therefore cannot be influenced by the trial treatment. CONCLUSIONS: All-cause mortality has low power, lacks generalisability and can obscure harmful effects. Cause-specific mortality, such as death due to bleeding or thrombosis, avoids these drawbacks. In certain scenarios, time-specific mortality can be used as a proxy for cause-specific mortality. Blood transfusion and surgical procedures have limited utility as outcome measures in trials of haemostatic treatments.
引用
- Brenner A, Arribas M, Cuzick J, et al. Outcome measures in clinical trials of treatments for acute severe haemorrhage. Trials. 2018. PMID: 30285839. doi:10.1186/s13063-018-2900-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。